Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 5,825 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 5,825 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at $488,660.76. This trade represents a 14.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Houte Hans Van also recently made the following trade(s):

• On Thursday, January 30th, Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35.

Nurix Therapeutics Trading Down 8.2 %

NASDAQ NRIX opened at $14.19 on Tuesday. The firm’s fifty day moving average price is $18.51 and its two-hundred day moving average price is $21.78. Nurix Therapeutics, Inc. has a 1 year low of $11.90 and a 1 year high of $29.56. The firm has a market capitalization of $1.08 billion, a P/E ratio of -4.91 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on NRIX shares. BTIG Research started coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price target for the company. Stifel Nicolaus upped their price target on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. reduced their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Stephens reiterated an “overweight” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Finally, Royal Bank of Canada upped their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and an average target price of $31.81.

Institutional Trading of Nurix Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRIX. US Bancorp DE raised its position in Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after acquiring an additional 842 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Nurix Therapeutics during the fourth quarter worth $28,000. Amalgamated Bank raised its position in Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after acquiring an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Nurix Therapeutics by 31.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after acquiring an additional 559 shares in the last quarter. Finally, Quarry LP raised its position in shares of Nurix Therapeutics by 3,746.2% in the third quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after purchasing an additional 2,435 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.